Archana Thakur

7PUBLICATIONS
27CO-AUTHORS
Tumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 12, 2025
LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapy.

Robert Weldon Barnes, Archana Thakur, Suna Onengut-Gumuscu

|Jul 14, 2025
LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell Therapy.

Robert Weldon Barnes, Archana Thakur, Suna Onengut-Gumuscu

|Sep 25, 2024
Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T.

Michael C Brown, Vincent M D'Anniballe, David Boczkowski

|Jun 10, 2024
Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer.

Elisabeth I Heath, Archana Thakur, Wei Chen

|Oct 18, 2022
Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.

Ulka N Vaishampayan, Archana Thakur, Wei Chen

|Sep 01, 2020
Anti-tumor and immune modulating activity of T cell induced tumor-targeting effectors (TITE).

Archana Thakur, Sri Vidya Kondadasula, Kyungmin Ji

Pageof 2

Frequent Collaborators

4 joint publications

Lawrence Lum

3 joint publications

Wei Chen

3 joint publications

Elisabeth I Heath

2 joint publications

Ulka N Vaishampayan